XML 63 R38.htm IDEA: XBRL DOCUMENT v3.25.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Schedule of Computation of Basic and Diluted Earnings Per Share
The table below presents the computation of basic and diluted earnings per share (in millions, except for per share information):
 Years Ended December 31,
 202420232022
Net Income for Earnings Per Share Calculations:  
Income from continuing operations, net of tax$1,396.0 $1,220.0 $1,324.0 
Net loss attributable to noncontrolling interests(4.9)(3.0)— 
Income from continuing operations attributable to Edwards Lifesciences Corporation1,400.9 1,223.0 1,324.0 
Income from discontinued operations2,773.7 179.4 197.9 
Net income attributable to Edwards Lifesciences Corporation$4,174.6 $1,402.4 $1,521.9 
Weighted Average Shares:
Basic weighted-average shares outstanding597.7 606.7 619.0 
Dilutive effect of stock plans1.6 2.7 5.2 
Dilutive weighted-average shares outstanding599.3 609.4 624.2 
Earnings per Share:
Basic:
Continuing operations$2.34 $2.02 $2.14 
Discontinued operations4.64 0.29 0.32 
Basic earnings per share$6.98 $2.31 $2.46 
Diluted:
Continuing operations$2.34 $2.01 $2.12 
Discontinued operations4.63 0.29 0.32 
Diluted earnings per share$6.97 $2.30 $2.44 
Schedule of Stock-Based Compensation Expense
Total stock-based compensation expense was as follows (in millions):
 Years Ended December 31,
 202420232022
Cost of sales$26.7 $20.6 $20.3 
Selling, general, and administrative expenses82.5 74.0 67.3 
Research and development expenses36.4 30.2 26.0 
Total stock-based compensation expense145.6 124.8 113.6 
Income tax benefit(24.8)(21.8)(19.6)
Total stock-based compensation expense, net of tax$120.8 $103.0 $94.0